Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca loses landmark Losec appeal

This article was originally published in SRA

Executive Summary

The General Court of the European Union has broadly upheld the fine imposed by the European Commission on AstraZeneca for abuse of a dominant position by blocking or delaying generic versions of its proton pump inhibitor, the anti-ulcer drug Losec (omeprazole)1. The move is expected to give support to the commission in its pursuit of antitrust actions against pharmaceutical companies; pharmaceutical industry federation EFPIA said the ruling could have a "chilling effect" on innovation2.

Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS115395

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel